Depleting all CD14+ cells (including monocytic MDSCs) in AML-PBMCs prior to AMG 330 treatment did not have a detectable effect on T-cell activation or their production of cytokines as well as T-cell expansion (Fig. 2e), which has been shown to be highly relevant for the clinical activity of BiTE® antibody constructs [18]. This evidence concerns the gene CD14 and acute myeloid leukemia.